Lushang Freda Pharmaceutical Co. Ltd. is a prominent company in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of medicinal products. The company is focused on producing a wide range of pharmaceuticals, including both prescription and over-the-counter drugs, catering to a diverse array of medical needs. In addition to its primary pharmaceutical offerings, Lushang Freda is also involved in the research and innovation of healthcare solutions, further strengthening its role in improving patient care and health outcomes. With its extensive product lineup, the company serves numerous sectors within healthcare, impacting hospitals, medical professionals, and individual consumers alike. Lushang Freda's presence in the market highlights its significance in contributing to the availability of critical medications, thereby supporting public health infrastructure and pharmaceutical supply chains. Through strategic partnerships and a commitment to quality, the company maintains a strong position in the competitive landscape of the pharmaceutical industry.
Industry
Real Estate Development
Real Estate sector · China
Coordination
Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination
Stories
Structural patterns identified in Lushang Freda Pharmaceutical Co. Ltd.
No stories identified yet.
Key Metrics
Market Capitalization
7.17BCNY
NormalMar 19, 2026
Trailing P/E
33.81CNY
NormalMar 19, 2026
Revenue (TTM)
3.78BCNY
NormalMar 19, 2026
Forward Yield
2.95%
Annual Rate
CNY 0.21
Paid unknown
Payout Ratio
52.4%
Sustainable
Loading dividend history...
Track Record
Frequency
Unknown
Payback Period
116.5 yr
Years to recoup investment via dividends alone
Upcoming
Ex-Dividend Date
Jul 24, 2025
Valuation9
Market Capitalization
7.17BCNY
NormalMar 19, 2026
Enterprise Value
5.40BCNY
NormalMar 19, 2026
Trailing P/E
33.81CNY
Similar Stocks
No similar stocks identified yet.
Related Articles
No related articles yet.
Profit Margin
5.67%
NormalMar 19, 2026
Beta
1.36CNY
NormalMar 19, 2026
52-Week Change
-6.72CNY
ExtremeMar 19, 2026
Forward Annual Dividend Yield
2.95%
NormalMar 19, 2026
Normal
Mar 19, 2026
Forward P/E
22.54CNY
NormalMar 19, 2026
PEG Ratio
22.54CNY
ExtremeMar 19, 2026
Price to Sales (TTM)
1.91CNY
NormalMar 19, 2026
Price to Book (MRQ)
1.72CNY
NormalMar 19, 2026
Enterprise to Revenue
1.43CNY
NormalMar 19, 2026
Enterprise to EBITDA
24.75CNY
NormalMar 19, 2026
Profitability & Growth58
Gross Margin
53.35%
NormalMar 19, 2026
Profit Margin
5.67%
NormalMar 19, 2026
Operating Margin
3.41%
NormalMar 19, 2026
Return on Assets (TTM)
0.0164CNY
NormalMar 19, 2026
Return on Equity (TTM)
0.0550CNY
NormalMar 19, 2026
Revenue (TTM)
3.78BCNY
NormalMar 19, 2026
Revenue per Share (TTM)
3.71CNY
NormalMar 19, 2026
Quarterly Revenue Growth
-0.0800CNY
NormalMar 19, 2026
Gross Profit (TTM)
1.97BCNY
NormalMar 19, 2026
EBITDA
356.21MCNY
ExtremeMar 19, 2026
Net Income (TTM)
214.11MCNY
NormalMar 19, 2026
Quarterly Earnings Growth (YoY)
-0.2310CNY
NormalMar 19, 2026
Operating Cash Flow (TTM)
205.94MCNY
NormalMar 19, 2026
Levered Free Cash Flow (TTM)
55.20MCNY
NormalMar 19, 2026
Forward Annual Dividend Rate
0.2100CNY
NormalMar 19, 2026
Forward Annual Dividend Yield
2.95%
NormalMar 19, 2026
Trailing Annual Dividend Rate
0.0600CNY
NormalMar 19, 2026
Trailing Annual Dividend Yield
0.84%
NormalMar 19, 2026
Payout Ratio
0.5238CNY
NormalMar 19, 2026
Minority Interest (Equity)
683.47M
NormalFY2024 · Dec 31, 2024
Revenue
3.98B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
1.88B
NormalFY2024 · Dec 31, 2024
Gross Profit
2.10B
NormalFY2024 · Dec 31, 2024
Operating Income
277.36M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
346.29M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
49.85M
NormalFY2024 · Dec 31, 2024
Net Income
296.44M
NormalFY2024 · Dec 31, 2024
EBIT
367.65M
NormalFY2024 · Dec 31, 2024
ebitda-income
502.65M
NormalFY2024 · Dec 31, 2024
Research & Development
166.77M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
1.39B
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
41.96M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
51.82M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
21.36M
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.2400
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.2400
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
1.01BShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
1.01BShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
296.44M
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
-52.92M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
465.05M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
71.44M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
2.80B
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
296.44M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
33.20M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
175.89M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
-40.49M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-156.89M
NormalFY2024 · Dec 31, 2024
Net Acquisitions
2.98B
NormalFY2024 · Dec 31, 2024
Sale of Investments
83.55M
NormalFY2024 · Dec 31, 2024
Other Investing Activity
83.99M
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
2.99B
NormalFY2024 · Dec 31, 2024
Long-term Debt Issuance
348.00M
NormalFY2024 · Dec 31, 2024
Long-term Debt Payments
-2.23B
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-183.57M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-5.04M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-2.08B
NormalFY2024 · Dec 31, 2024
Financial Strength28
Shares Outstanding
1.02BShares
NormalMar 19, 2026
Float Shares
464.77MCNY
NormalMar 19, 2026
% Held by Insiders
0.5718CNY
NormalMar 19, 2026
% Held by Institutions
0.0268CNY
NormalMar 19, 2026
Total Cash (MRQ)
2.75BCNY
NormalMar 19, 2026
Total Cash per Share (MRQ)
2.71CNY
NormalMar 19, 2026
Total Debt (MRQ)
200.07MCNY
NormalMar 19, 2026
Total Debt to Equity (MRQ)
4.09CNY
AboveNormalMar 19, 2026
Current Ratio (MRQ)
4.51CNY
AboveNormalMar 19, 2026
Book Value per Share (MRQ)
4.12CNY
NormalMar 19, 2026
Total Assets
6.00B
NormalFY2024 · Dec 31, 2024
Total Current Assets
4.14B
NormalFY2024 · Dec 31, 2024
Total Liabilities
1.21B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
1.86B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
105.63M
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
1.11B
NormalFY2024 · Dec 31, 2024
Cash
1.03B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
1.77B
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
2.95B
NormalFY2024 · Dec 31, 2024
Accounts Receivable
403.05M
NormalFY2024 · Dec 31, 2024
Inventory
558.71M
NormalFY2024 · Dec 31, 2024
Accounts Payable
413.35M
NormalFY2024 · Dec 31, 2024
Short-term Debt
233.84M
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
23.15M
NormalFY2024 · Dec 31, 2024
Long-term Debt
52.09M
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
1.02B
NormalFY2024 · Dec 31, 2024
Retained Earnings
2.21B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
4.79B
NormalFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
6.70CNY
NormalMar 19, 2026
52-Week High
9.42CNY
NormalMar 19, 2026
52-Week Change
-6.72CNY
ExtremeMar 19, 2026
Beta
1.36CNY
NormalMar 19, 2026
50-Day MA
7.38CNY
NormalMar 19, 2026
200-Day MA
7.83CNY
NormalMar 19, 2026
Avg 10-Day Volume
5.93MCNY
NormalMar 19, 2026
Avg 30-Day Volume
10.09MCNY
NormalMar 19, 2026
Diluted EPS (TTM)
0.2100CNY
NormalMar 19, 2026
Screen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.